|
Aug 15
|
Atai Life Sciences Second Quarter 2025 Earnings: US$0.14 loss per share (vs US$0.36 loss in 2Q 2024)
|
|
Aug 14
|
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
|
|
Aug 1
|
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10
|
|
Jul 28
|
Trade Outlook Buoys US Equity Futures Pre-Bell
|
|
Jul 28
|
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
|
|
Jul 28
|
Atai backs away from schizophrenia drug after trial failure
|
|
Jul 28
|
Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
|
|
Jul 25
|
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
|
|
Jul 21
|
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
|
|
Jul 11
|
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
|
|
Jul 11
|
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
|
|
Jul 1
|
A Promising Depression Drug Works. Psychedelics Are Back.
|
|
Jul 1
|
atai and Beckley Psytech’s psychedelic wins in Phase IIb depression trial
|
|
Jul 1
|
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
|
|
Jul 1
|
Atai and Beckley, set to merge, reveal study success for psychedelic drug
|
|
Jul 1
|
atai Life Sciences Announces $50 Million Private Placement Financing
|
|
Jul 1
|
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
|
|
Jun 25
|
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
|
|
Jun 24
|
Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target
|
|
May 29
|
atai Life Sciences to Participate in Upcoming Investor Conferences
|